This center is a multidimensional program developed for the study of thrombotic disorders involving the arterial, venous, and microcirculatory systems.
Multidisciplinary collaborations provide a foundation for basic, translational, clinical (phase 1, 2, and 3), and population science investigation for students, housestaff, fellows, and faculty.
The center's collaborators include:
- The Duke Clinical Research Institute
- The Comprehensive Center for Thrombosis and Hemostasis: This multidisciplinary initiative includes representation from the Divisions of Hematology, Cardiovascular Medicine, and Neurology; the Departments of Cardiothoracic Surgery, Vascular Surgery, Pathology, Pediatrics, Obstetrics and Gynecology, and Molecular Biology; and the Institute for Genomic Science and Policy.
The center leads a National Thrombogenics Network, known as Helix, which is assembling a database of 50,000 patients via a nationwide network of anticoagulation clinics. Blood samples will be used to conduct genomic, proteomic, and biomarker studies.
- Becker RC. The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort. European Heart Journal 2005;26(5):421-42.
- Becker RC. Thrombin: science and application in clinical practice. American Heart Journal 2005;149(1 Suppl):S1.
- Becker RC. Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. American Heart Journal 2005;149(1 Suppl):S2-S8.
- Becker RC. Novel constructs for thrombin inhibition. American Heart Journal 2005;149(1 Suppl):S61-S72.
- Becker RC. Alexander J. Li YF. Bovill E. Spencer FA. Robertson TL. Kunitada S. Dyke CK. Harrington RA. Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. Thrombosis & Haemostasis 2004;92(6):1229-1231.
- Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized placebo-and active-controlled trial. Am Heart J 2006;151:689.e1-689.e10.
- Becker KC, Becker RC. Nucleic Acid Aptamers as adjuncts to vaccine development. Curr Opin Molec Therap 2006;8:122-129.
Richard C. Becker, MD
Office: 2400 Pratt Street Durham, NC, 27710
Campus mail: DUMC Box 3850, Durham, NC, 27710